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Summary 
Stimulation of heparinized  blood with 1 #M formyl-methionyl-leucyl-phenylalanine  (FMLP) 
resulted  in the formation of <30  pmol/ml plasma  of 5-1ipoxygenase (5-LO)  products.  The 
preincubation of blood with 1 I~g/ml of lipopolysaccharide (LPS) (Escherichia coli 0111-B4) for 
30 min before stimulation with FMLP resulted in the accumulation of 250-300  pmol of 5-LO 
products per ml plasma. The major products detected were leukotriene B4 and (SS)-hydroxy-6, 
8, 11, 14-eicosatetraenoic acid which were produced in equivalent amounts. The priming activity 
was detectable with as little as 1-10 ng LPS per ml blood and was optimal using 1-10/tg LPS/ml 
blood. The priming for 5-LO product synthesis was optimal after 20-30 min of preincubation 
with LPS and declined at preincubation times >30 min. The priming effect of LPS was also 
observed using the complement fragment C5a or interleukin 8 as agonists. Polymorphonuclear 
leukocytes (PMN) and peripheral blood mononudear cells accounted  for 80 and 20%  of the 
synthesis of 5-LO products, respectively. The ability of LPS to prime isolated PMN was dependent 
on the presence of plasma and was inhibited by the anti-CD14  antibody IOM2, indicating a 
CD14-dependent priming mechanism. The priming of whole blood with tumor necrosis factor 
c~ (TNF-o  0 and LPS was additive and the presence of mononudear cells did not enhance the 
ability of LPS to prime PMN, indicating that the priming activity of LPS is independent of 
LPS-induced TNF-c~ synthesis. The mechanism by which LPS enhance 5-LO product synthesis 
in PMN was investigated. Treatment of PMN with LPS strongly enhanced the release  of arachidonic 
acid after stimulation with FMLP. The release of arachidonic acid was optimal 2-3 min after 
stimulation with FMLP, attaining levels 5-15-fold greater than those observed in unprimed cells 
stimulated with FMLP. These results demonstrate that LPS dramatically  increases the ability 
of blood to generate 5-LO products, and support the putative role of leukotrienes in pathological 
states involving LPS. 
T 
he brisk inflammatory reaction which occurs in response 
to gram-negative pathogens is largely induced by LPS 
(or endotoxin), which directly stimulate leukocytes for a host 
of defensive responses (1-5). Indeed, when exposed to LPS, 
leukocytes release  prostaglandins (6), exhibit increased expres- 
sion of CD11b/CD18 and adhesion (7-9), and produce cyto- 
kines such as IL-1 (10) and TNF-cr  (11). Additionally,  LPS 
prime leukocytes in vitro for an increased capacity for several 
functional responses, including arachidonate release  from mac- 
rophages (12, 13), as wen as leukotriene (14), platdet-activating 
factor (15), and superoxide production (16-18) by neutrophils. 
In localized infections, LPS are largely restricted  to inflam- 
matory sites, enhancing host defense. However, if the infec- 
tion is not brought under control, endotoxin and/or inflam- 
matory mediators may reach the circulation, predisposing the 
microvasculature to thrombosis (2) and can lead to systemic 
endotoxemia or sepsis and associated complications including 
septic shock (19), adult respiratory distress syndrome (ARDS) 
(20),  and multiorgan failure (21). 
Leukotriene B4 (LTB4) 1,  one of the most potent inflam- 
matory chemoattractants (22, 23), and other arachidonic acid 
(AA) metabolites such as (5S)-hydroxy-6,8,11-14-eicosatetrae- 
noic acid (5-HETE) are produced by the 5-1ipoxygenase  (5-LO) 
pathway of neutrophils and monocytes-macrophages  upon 
1Abbrevations used in this paper: AA, arachidonic  acid;  5-HETE,  (5S)- 
hydroxy-6,8,11,14-eicosatetraenoic acid; 5-LO, 5-1ipoxygenase; LBP, LPS 
binding  protein;  LT, leukotfiene;  LTB4, leukotriene  B4; PGB, prosta- 
glandin  B2. 
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are the primary effector cells in inflammation,  are also inti- 
mately involved in the pathogenesis of sepsis and associated 
complications (2, 19, 21, 24, 25). Likewise, 5-LO products 
have been implicated in LPS-induced endotoxic shock, pul- 
monary granulocyte sequestration, and pulmonary dysfunc- 
tion  and liver damage (26-30).  Akhough  neutrophils  and 
AA metabolites from the 5-I.O pathway are implicated in 
the defensive inflammatory responses to bacteria, as well as 
in the complications resulting from uncontrolled infections, 
there is limited information  concerning  the effects of bac- 
terial LPS on the metabolism of 5-LO products in these cells. 
Whereas LPS do not directly stimulate neutrophils  for the 
synthesis of 5-LO products, LPS have been shown to prime 
isolated neutrophils for an enhanced synthesis of LTB4 in re- 
sponse  to  subsequent  stimuli  like the ionophore  A23187, 
phorbol  ester,  or  zymosan,  but  not  to  receptor-mediated 
stimuli  (14).  Similarly,  mouse peritoneal macrophages and 
macrophage-like P388D1 cells primed with LPS release more 
AA metabolites after stimulation than unprimed cells (12, 13). 
The induction of several leukocytic responses by LPS re- 
cently has been shown to require the presence of the plasma 
proteins LPS binding protein  (LBP) or septin which form 
complexes with LPS that are recognized by the cellular CD14 
surface antigen (31-33). Importantly,  these plasma proteins 
have been shown to be obligatory for LPS-induced leukocyte 
responses such as superoxide anion production, cell adhesion, 
integrin expression, and TNF-ol secretion (7, 9, 18, 31, 33, 
34). Few reports describe leukotriene (LT)  synthesis in the 
presence of plasma or in blood (35) and none investigates 
the effect of LPS on LT synthesis in such conditions.  The 
involvement of plasma proteins in cellular responses to LPS, 
coupled with the potentially complex dynamics of AA me- 
tabolism in vivo where transcellular synthesis of AA metab- 
olites occurs (35-38), and where plasma may also affect AA 
metabolism (39, 40), underscores the importance of the study 
of the effects of LPS on lipid mediator synthesis in a physio- 
logically relevant environment. 
Human whole blood has been successfully used as an ex 
vivo model for local cytokine production  (41-43) and AA 
metabolism (35, 44). The use of this readily available intact 
human tissue reduces potential artifacts arising from cellular 
isolation procedures (45) and provides a physiological envi- 
ronment where cellular interactions are preserved. The present 
study characterizes the priming of leukocytes by LPS for the 
subsequent synthesis of 5-I.O products in whole blood stimu- 
lated with  soluble agonists. 
Materials and Methods 
Materials.  Biosynthetic recombinant human TNF-ce and GM- 
CSF were a gift from the Genetics Institute  (Cambridge,  MA). 
Recombinant human IL-8 was a gift from Dr. Henry Showell (Pfizer 
Pharmaceuticals, Groton, CT). LPS (Escherichia coli 0111-B4) was 
obtained from Difco Laboratories (Detroit,  MI) and HBSS from 
GIBCO BRL (Burlington, Ont., Canada). Purified anti-CD14 mAb 
(IOM2) was obtained from AMAC Inc., (Westbrook, ME). The 
calcium ionophore A23187, recombinant human C5a, FMLP, and 
prostaglandin  B2 (PGB2) were obtained  from  Sigma Chemical 
Company (St. Louis, MO). AA and deuterated- (Ds) AA were ob- 
tained from Cayman Chemical Co. (Ann Arbor, MI). 19-hydroxy- 
PGB2 was prepared as previously described (46). TNF-o~, GM- 
CSF, and Ib8 were dissolved in nonpyrogenic  water containing 
0.01% BSA (low endotoxin),  under sterile conditions, and stored 
at  -20~  LPS was dissolved in 0.9% NaC1. A23187 and FMLP 
were prepared in DMSO which had been faltered on ahmin. Lyophi- 
lized C5a was reconstituted  at 1 mg/ml in nonpyrogenic water. 
Ficoll-Paque (Pharmacia, Uppsala, Sweden) and water used for the 
preparation of various solutions were tested for endotoxin content 
by the Limulus Amebocyte Lysate Assay (Whittaker Bioproducts, 
Walkersville, MD) and found to contain endotoxin in the low pg/ml 
levels. All  solutions  and reagents  used for cell preparation  and 
priming  were sterile. 
Blood Incubations.  Venous blood was obtained  from healthy 
donors and coUected into 10-cc glass tubes (100 x  16 mm Vacu- 
tainer; Becton Dickinson & Co., Mountain View, CA) containing 
143 USP units of heparin. All donors had normal differential leu- 
kocyte counts.  Heparinized blood was preincubated  in the pres- 
ence of LPS or its diluent  at 37~  for 30 min unless otherwise 
indicated. The blood was then dispensed in polypropyhne tubes 
(0.5 ml per tube) and incubated in a shaking water bath at 37~ 
for 15 min in the presence of DMSO (0.2%), FMLP, C5a, or Ib8. 
Incubations were stopped at 0~  (ice-water  bath) and blood samples 
were immediately centrifuged at 400g for 3 min at 4~  A 200-/~1 
aliquot of plasma was collected from each sample and added to 5 
vol of acetonitrile/methanol  (1:1, vol/vol) containing 12.5 ng each 
of PGB2 and  19-hydroxy-PGB2 as  internal  standards.  Protein 
precipitation was achieved at  -20~  overnight before analysis of 
5-LO products  by HPLC (44). 
Isolated Cell Preparations.  PMN and PBMC were isolated from 
peripheral blood after dextran sedimentation and centrifugation on 
Ficoll-Paque cushions  as  previously  described  (47). Leukocyte- 
depleted blood was obtained by removal of the buffy coat after four 
successive  centrifugations of whole blood and resuspensions of the 
sedimented RBC with autologous plasma. The final RBC prepa- 
ration  containing  <5%  of the normal blood leukocytes was re- 
suspended in autologous  plasma (1:1, vol/vol) and referred to as 
leukocyte-depleted  blood. In some experiments, PMN and/or PBMC 
were resuspended at 5  x  106 and 3.5  x  106 cells, respectively, per 
ml of autologous  leukocyte-depleted blood. 
Blocking Studies with Anti-CD14.  For blocking studies, 5  x  106 
PMN were suspended in 200/~1 of calcium-free HBSS containing 
(or not) 5/~g of purified IOM2 anti-CD14 mAb, which was previ- 
ously shown to inhibit  the specific binding of LPS to monocytes 
(48), or 5/~g of an isotype control antibody for 30 min at 4~ 
The cells were then washed and resuspended in HBSS supplemented 
with 10% heat-inactivated autologous plasma and incubated in the 
presence or absence of LPS (1/~g/ml)  or GM-CSF (1 riM) for 30 
min  at  37~  The  cells were  washed  once by centrifugation, 
resuspended in HBSS, and stimulated with FMLP (0.1/~M)  for 
10 min. Reactions were stopped by the addition of 1 vol of organic 
solvents containing standards (see  blood incubations above)  and 5-1.O 
products  were analyzed as described below. 
Analysis  of 5-Lipoxygenase  Products.  The  denatured  samples 
(plasma or isolated  leukocyte  suspensions) were  centrifuged  at 
2,000 g for 20 rain to remove the precipitated material, the super- 
natants were diluted to 75% water and analyzed without further 
treatment by reverse phase (RP) HPLC using an on-line extraction 
procedure as described previously (44, 46). 
Analysis of Free Arachidonic Acid in Isolated PMN.  Isolated neu- 
trophils were preincubated for 30 rain at 37~  in HBSS containing 
10% plasma with or without 1/~g/ml LPS. After the preincuba- 
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in plasma-free  HBSS. Cells were then stimulated with 0.1 #M FMLP 
at 37~  and at various times the incubations were terminated by 
the addition of 2 vol of ice-cold methanol containing 20 ng of Ds- 
AA as an internal standard. Samples were processed as described 
above for HLPC analysis and the HPLC fractions containing AA 
(determined  by using  a 3H-AA standard) were  collected.  The 
samples were evaporated  under reduced pressure (using a Speed Vac 
model SVC 10(O; Savant Instruments Inc., Farmingdale, NY) and 
redissolved into 100 ttl of acetonitrile. AA was assayed by liquid 
chromatography-mass spectrometry (LC-MS), using a nebulizer- 
assisted electrospray (ion  spray) interface  coupled  to  a  triple- 
quadrupole MS (API-III; PE Sciex, Thornhill, Ont., Canada). 6 
ttl aliquots of the samples were injected into the electrospray inter- 
face via the 20-/~1 loop of a ILheodyne injector (model 9125; Rheo- 
dyne, Cotati, CA) connected to a short column (2 x 30 ram, packed 
with  5  ttm  Cls  particles),  using  acetonitrile:H20  (87.5:12.5, 
vol/vol, containing 0.1% acetic acid) as solvent, at a flow rate of 
150 #l/min. Samples were analyzed in the negative ion mode. The 
ions at m/z 303 and 311, representing the carboxylate anions of 
AA and Ds-AA, respectively, were monitored. 
Results 
LPS Priming of Blood  for the Synthesis of S-LO Products: Ki- 
netics and Dose-Responsr  After preincubation with LPS, the 
stimulation of blood with 1/~M FMLP resulted in the syn- 
thesis of 5-HETE,  LTB4 and the ~0-oxidation products of 
LTB4,  20-hydroxyl-LTB4 (20-OH-LTB4), and  20-COOH- 
LTB4, as shown on the HPLC-chromatograms (Fig.  1).  In 
the absence of LPS, stimulation of  blood with FMLP resulted 
in a much smaller yet detectable synthesis of 5-LO products. 
The priming effect of LPS was rapid,  maximal capacity 
for the synthesis of 5-LO products being observed after 30 
min of preincubation of blood with 1 #g LPS/ml (Fig. 2). 
The synthetic capacity of blood rapidly decreased at longer 
preincubation times, and the priming effect of LPS was no 
longer detectable at 90-240 min (data not shown). The prein- 
cubation of blood in the absence of added LPS, followed by 
stimulation with FMLP, resulted in little or no significant 
synthesis of 5-LO products at any of  the time intervals tested. 
When blood was preincubated for 30 min with varying con- 
centrations of LPS before stimulation with 1/~M FMLP, a 
priming effect for the synthesis of 5-LO products was ob- 
served with as little as 1-10 ng LPS per ml of blood. The 
maximal priming response was obtained in samples prein- 
cubated with 1/~g LPS per ml of blood (Fig. 3). The prein- 
cubation of blood with LPS, without subsequent FMLP stim- 
ulation, resulted in little if any synthesis of 5-LO products 
except at the higher LPS concentrations (1-10 #g/ml) where 
LPS alone induced the synthesis of LTB4 in amounts equiva- 
lent to '~5% of the amount synthesized after FMLP stimu- 
lation of LPS-treated blood (data  not shown). 
The predominant 5-LO products detected in blood primed 
with  LPS  and  stimulated  with  FMLP  were  LTB4 and 
5-HETE which were synthesized in approximately equiva- 
lent amounts.  Typically,  125-150 pmol of each compound 
was detected per ml of plasma obtained from blood primed 
with 1/xg LPS for 30 min and subsequently stimulated for 
15 min with 1/~M FMLP. However, the magnitude of the 
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Figure 1.  RP-HPLC  chromatograms  of eicosanoids  in plasma samples. 
Heparinized blood aliquots were preincubated  for 30 min at 37~  with 
1 #g/ml LPS (/3) or its diluent (0.9% NaC1) (/1) before  stimulation for 
15 min with 1 ttM FMLP. Plasma samples (200  ttl) were  taken  and processed 
for analysis by R.P-HPLC as described in Materials and Methods. The 
amount of internal standards added per sample was 12.5 ng each of PGB2 
and 19-OH-PGB2,  and 80% of each sample was injected. Attenuation  set- 
tings of the UV photodiode  array  detector  were  0.01 and 0.05 absorbance 
units at full scale at 270 and 234 nm, respectively. 
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Figure 2.  Kinetics  of the priming effect of LPS on the synthesis of 
LTB4 (open squares), its ~oxidation products 20-OH- and 20-COOH- 
LTB4 (filled squares), and 5-HETE (open  circles) in whole blood stimulated 
with FMLP. Heparinized human blood was preincubated with LPS (1 
ttg/ml) for various periods of time before stimulation for 15 min with 
1 tiM FMLP. 5-LO products were analyzed  by ILP-HPLC  as described 
in Materials and Methods. Values are the means _+ SD from one experi- 
ment performed  in triplicate  which is representative  of four separate ex- 
periments. 
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Figure  3.  The dose-response  of the priming effect of LPS on the syn- 
thesis of LTB4 (open squares), its w-oxidation  products  20-OH- and 20- 
COOH-LTB4 (filled squares), and 5-HETE (open circles) in whole blood 
stimulated with FMLP. Heparinized human blood was preincubated with 
the indicated concentrations  of LPS for 30 min before stimulation  for 15 
min with 1/~M FMLP.  5-1.O products  were analyzed by RP-HPI.C as 
described  in Materials  and Methods.  Values are the means  _+  SD from 
one experiment  performed in triplicate  which is representative of six ex- 
periments. 
response ranged from 50 to 200 pmol of LTB+ or 5-HETE 
per ml of plasma, depending on the donor. The co-oxidation 
metabolites of LTB4,  20-OH-LTB4,  and  20-COOH-LTB4, 
were detected in amounts representing ~10-20% of the quan- 
tity of LTB4 measured, independently of the incubation time 
with FMLP. 
Effect of LPS on the Synthesis of S-LO Products Induced by 
Various Agonists.  The chemotactic formylated bacterial tripep- 
tide, FMLP, was a more potent agonist for the stimulation 
of 5-LO products in LPS-primed blood than were the human 
complement fragment C5a or the chemoattractant IL-8 (Fig. 
4). In dose-response studies, optimal synthesis of 5-LO prod- 
ucts in blood primed with 1 #g LPS/ml was obtained with 
0.5 pM of human C5a (data not shown). However, this only 
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Figure  4.  Effect of FMLP, C5a, or IL-8 on the synthesis of LTB4 in 
LPS-treated whole blood. Heparinized human blood was preincubated with 
1/~g/ml LPS for 20 min before stimulation  for 15 min with 1/~M FMLP, 
0.5/~M CSa, 0.5/~M IL-8, or their diluents.  LTB4 and its c0-oxidation 
metabolites  were analyzed  by R.P-HPI.C  as described in Materials  and 
Methods.  Values are the meam of three separate experiments  each per- 
formed in triplicate  •  SEM and represent the total amount of LTB4 and 
its o~-oxidatinn metabolites.  The values in all columns are significantly 
different from one another as de~ermined  by analysis of variance  using Fisher's 
protected least significant difference, p <0.05. 
resulted in half the synthetic capacity observed when using 
1 #M FMLP as the stimulus. Stimulation of LPS-Fimed blood 
with the highest concentration of IL-8 tested, 0.5 #M, only 
resuhed in a response equivalent to ,,010% of that observed 
with FMLP stimulation. 
Contribution of  PMN and Mononuclear Cells in the LPS Priming 
of Blood.  As indicated in Fig. 5, "~80% of the 5-LO prod- 
ucts detected in LPS-primed blood are released by PMN 
whereas the remaining 20% of the activity is found in the 
PBMC fraction. This was determined by adding either iso- 
lated PMN or PBMC, in physiological concentrations, to au- 
tologous leukocyte-depleted blood. Leukocyte-depleted blood 
alone, when preincubated with 1 #g/ml LPS, did not syn- 
thesize any detectable 5-LO products after stimulation with 
1 #M FMLP. Importantly, when both PMN and PBMC were 
added to the leukocyte-depleted blood, the capacity for the 
synthesis of 5-LO products resulting from a preincubation 
with LPS was equal to the sum of the synthetic capacities 
of blood partially reconstituted with the two leukocyte popu- 
lations separately. 
Dependence on Plasma and CDI4 for LPS Priming Activity. 
The requirement for plasma in the priming effect of LPS for 
the synthesis of 5-LO products was determined using iso- 
lated PMN. PMN were isolated and preincubated with var- 
ious concentrations of LPS in HBSS alone or in HBSS sup- 
plemented with 10% plasma, for 30 min at 37~  After the 
preincubation period, the cells were washed by centrifuga- 
tion, resuspended in HBSS, and stimulated for 10 min with 
0.1 #M FMLP. Fig. 6 demonstrates that the ability of LPS 
to prime neutrophils for an enhanced synthesis of 5-LO prod- 
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Figure  5.  The priming by LPS of leukocyte-depleted  human  blood 
(LDB) or leukocyte-depleted blood partially reconstituted with the PBMC 
fraction  (3.5  x  10  ~ ceUs/ml), the PMN fraction  (5  x  106 cells/ml),  or 
both fractions  (PMN+PBMC),  for the synthesis of 5-I.O products  fol- 
lowing stimulation with FMLP. The different fractions of  blood were prein- 
cubated  with 1/~g LPS/ml for 20 min at 37~  before stimulation for 
15 min with 1/~M FMLP. 5-LO products  were analyzed by RP-HPI.C 
as described in Materials and Methods.  Values are the means  _+  SD from 
one experiment  performed in triplicate  which is representative  of three 
separate  experiments.  Values represent  the  total  amount  of LTB4, its 
r  metabolites,  and  5-HETE. 
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Figure  6.  Effect  of plasma on the priming of PMN with LPS. PMN 
were isolated and preincubated for 30 min (at 107 cells/ml) with 1 t~g/ml 
LPS at 37~  in the absence (open squares) or presence (filled squares) of 
10% autologous plasma in HBSS. The cells were then washed by centrifu- 
gation, resuspended in 0.5 ml HBSS (at 107 cells/ml), and stimulated for 
10 rain with 0.1/~M FMLP. 5-LO products were analyzed by RP-HPLC 
as described in Materials and Methods. Values are the means +  SD from 
one experiment performed in triplicate which is representative of three 
separate experiments. 
ucts  in response  to  FMLP  was dependent  on  the presence 
of plasma during  the  preincubation  period. 
The dependence on plasma for the priming effects of LPS 
on 5-LO product synthesis suggested the involvement of in- 
teractions with the CD14 antigen.  Therefore,  the ability of 
the anti-CD14  mAb,  IOM2,  to block the priming activity 
of LPS was assessed.  When  the  IOM2-treated  PMN  were 
incubated with 1/~g/ml LPS, their response to FMLP stim- 
ulation was significantly decreased compared with cells prein- 
cubated in the absence of IOM2 (Fig.  7). In contrast, prein- 
cubation with the antibody did not block the priming activity 
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Figure 8.  Additivity of the priming effect of LPS and TNF-ot in blood. 
Heparinized human blood was preincubated with the indicated concen- 
trations of LPS with or without 1.2 nM TNF-ot for 30 rain before stimu- 
lation for 15 rain with 1/zM FMLP. 5-1.O products were analyzed by 
RP-HPLC as described in Materials and Methods. Values are the means 
_+ SD from one experiment performed in triplicate which is representa- 
tive of four separate experiments and represent the total amount of LTB4 
and its c0-oxidation metabolites. 
of GM-CSF, which is known to prime the cells via its own 
receptor,  and  the priming activity of LPS was not  affected 
by the preincubation of cells with isotype control antibodies. 
LPS  Priming  Activity  in  Whole  Blood:  Comparisons  with 
TNF-cr.  The potential role ofLPS-induced TNF-cr produc- 
tion  in  the  priming  of blood  by LPS for the  synthesis  of 
5-LO products  was investigated.  In a  first series of experi- 
ments,  the priming activity of LPS and TNF-ol were com- 
pared.  The preincubation  of blood with  1/zg LPS/ml rou- 
tinely resulted in a two- to fourfold greater synthesis of 5-LO 
products  after stimulation  with  FMLP  than  that  observed 
with blood pretreated with TNF-ol under optimal conditions 
(1.2  nM,  20 min,  data not  shown).  These results  indicate 
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Figure  7.  Effect  of the anti-CD14 mAb (IOM2) on the priming effect 
of LPS and of GM-CSF on LTB4 synthesis by FMLP-stimulated PMN. 
PMN were isolated and incubated on ice for 30 min with no addition 
(open bars), with IOM2 (1/~g/106 cells) (stippled bars), or with an IgG2a 
isotype control (1/zg/106 cells) (filled bars). Cells were then incubated for 
30 min with 1/zg/ml LPS or 1.0 nM GM-CSF in 10% autologous plasma 
at 37~  washed, and then stimuhted for 10 min with 0.1 #M FMLP. 
5-LO products were analyzed by RP-HPLC as described in Materials and 
Methods. Values are presented as the percent synthesis of LTB4 (and its 
w-oxidation metabolites) compared to incubations in the absence of anti- 
body (control). Values are from one experiment performed in duplicate 
which is representative of three separate experiments. 
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Figure  9.  Effect  of priming with LPS on the level of free AA in PMN 
suspensions. PMN were isolated and preincubated for 30 rain with 1 lag/ml 
LPS (open squares) or diluent (filled squares) at 37~  in HBSS containing 
10% autologous plasma. The cells were then washed by centrifugation, 
resuspended at a density of 107 cells/ml in HBSS, and 0.5 ml aliquots of 
the cell suspensions were stimulated with 0.1/*M FMLE Reactions were 
stopped with 3 vol of methanol (0~  containing 20 ng of deuterated 
(DS)-AA as an internal standard. Samples were subjected to HPLC and 
fractions containing AA were collected for quantitation by mass spectrom- 
etry. Values are the means from one experiment performed in duplicate 
which is representative of four separate experiments. 
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sible for the observed priming activity of LPS in blood. 
To determine possible interactions between LPS and TNF-ot 
in the observed priming effect, blood was primed with a range 
of LPS concentrations alone or in combination with TNF-c~ 
(1.2 riM). At all concentrations of LPS tested, coincubation 
with TNF-ot resulted in a priming activity equivalent to the 
sum of that of TNF-ot alone and LPS alone (Fig. 8). This 
suggests that LPS and TNF-oe are priming blood via different 
mechanisms and further indicates  that TNF-cz production 
was not involved in the priming activity of LPS for the syn- 
thesis  of 5-LO products in whole blood. 
Effect of  LPS Priming on Free AA Levels in Stimulated PMN. 
Levels of free AA were determined by mass spectrometric 
analysis in LPS-primed and unprimed PMN after stimula- 
tion with FMLP. Fig. 9 demonstrates that the levels of free 
AA in LPS-primed cells increase significantly within 30 s after 
stimulation with FMLP attaining maximal levels 2-3 min 
after stimulation. The peak in KA levels obtained varied from 
donor to donor, reaching levels from 5-15-fold above base- 
line. In contrast, unprimed cells only show a minor increase 
in AA levels after stimulation with FMLP.  In the absence 
of stimulation, the basal levels of free AA were the same in 
primed and unprimed cells, indicating that LPS alone did 
not induce an increase in the levels of free AA. 
Discuss/on 
Bacterial LPS prime leukocytes for enhanced functional ca- 
pacities (15, 16, 17, 49), including AA metabolism (12-14, 
50). Because of the already accumulated evidence for a role 
of leukotrienes in pathological states related  to sepsis, and 
given the recent demonstration that plasma proteins are re- 
quired for the stimulation by LPS of functional responses by 
leukocytes,  we sought to study the effects of LPS on the 
production 5-LO products in whole blood ex vivo, a model 
relevant to physiological and pathophysiological conditions. 
The data reported herein demonstrate that LPS efficiently 
prime whole blood ex vivo for the subsequent synthesis of 
LTB4 and  5-HETE  after  stimulation with  the  receptor- 
mediated soluble agonists FMLP, C5a or IL-8. This is in con- 
trast to the reported lack of priming effect of LPS in isolated 
neutrophils stimulated with FMLP in protein-flee buffer (14). 
Similar to the priming effect of LPS on 02- release (8) and 
to the direct effect of LPS on CR3 activity in PMN (7), the 
priming effect of LPS on 5-LO product synthesis was transient. 
The synthesis of 5-LO products induced by FMLP in LPS- 
primed blood was compared with that induced by C5a and 
IL-8 which are also known to activate human neutrophil 5-LO 
(51, 52) and which are implicated in the pathophysiological 
response to LPS (1, 53). IL-8 (0.5/*M) was a weak agonist 
for 5-LO product synthesis in whole blood although the con- 
centration used was relatively elevated compared with con- 
centrations required for optimal biological activity in isolated 
neutrophils. The binding of IL-8 to erythrocytes and to cir- 
culating anti-IL-8 IgG in plasma were recently reported and 
may be mechanisms by which circulating IL-8 is neutralized 
(54,  55).  However,  the concentrations of IL-8 used in the 
present study far exceed the reported binding capacities of 
erythrocytes or anti-IL-8 IgG. Consequently, these binding 
activities do not explain the relatively low activity for IL-8 
reported in this model. 
An important difference in the LPS priming of whole blood 
compared with isolated cells may be the participation of plasma 
proteins in the binding of LPS to leukocytes. Numerous leu- 
kocytic cell-surface proteins have been described which bind 
LPS (56).  One cell-surface protein whose interaction with 
LPS invokes cellular responses is the CD14 antigen which 
was first described as a monocyte/macrophage  differentiation 
antigen (32). LPS binding to CD14 requires the presence of 
plasma since the ligand for CD14 is actually a complex of 
LPS with plasma proteins. Two separate proteins, LBP and 
septin, have been identified which, when complexed to LPS, 
form the ligand for CD14 (31, 33). The priming of PMN, 
which represent 85%  of the CD14-positive cells in blood 
as determined by cytofluorometric analysis (data not shown), 
was dependent on plasma and was blocked by pretreatment 
of cells with an anti-CD14 blocking antibody indicating that 
the effect of LPS observed here is mediated via the CD14 
receptor. Additionally, preincubation of PMN with the anti- 
body had no effect on the synthesis of 5-LO products when 
cells were subsequently primed with GM-CSF and stimu- 
lated with FMLP, indicating that the antibody specifically 
inhibited the cellular response to LPS and not the ability to 
synthesize 5-LO products, nor the response to FMLP. 
Pathologies associated with bacteremia have been suggested 
to result at least in part from LPS-induced TNF-ot produc- 
tion (57). Monocytes or macrophages incubated in the pres- 
ence of LPS secrete important quantities of TNF-c~ which 
itself can activate or prime cells for enhanced cellular func- 
tions including LTB4 synthesis (58).  This raises the possi- 
bility that the priming effect observed in the present study 
on the synthesis of 5-LO products may be mediated by LPS- 
induced TNF-c~ synthesis. Several  observations, however, argue 
against this hypothesis. The finding that the priming activity 
of optimal concentrations of TNF-ot is additive with various 
concentrations of LPS suggests that LPS prime blood for the 
synthesis of 5-LO products independently  of TNF-ol. An in- 
crease in the TNF-o~ concentration in plasma is only detected 
1 h after the treatment of blood with LPS, with maximal 
production at 4-6 h (41, 42), whereas LPS priming of 5-LO 
product synthesis is optimal within 30 min. Furthermore, 
the priming effect of LPS in blood enables the synthesis of 
5-LO products which is of severalfold greater magnitude than 
that achieved with optimal concentrations of TNF-cz (1.2 
nM) (data not shown). Finally, the presence of mononuclear 
cells, which are the principle cells responsible  for cytokine 
synthesis in blood (including TNF-cx),  did not affect LPS 
priming of PMN, suggesting that LPS is acting directly on 
granulocytes with no contribution from monocyte secretory 
products. LPS priming of isolated PMN further supports this 
hypothesis. 
The mechanisms by which LPS or cytokines prime leuko- 
cytes for an increased synthesis of 5-LO products have not 
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ucts may result from an increased activity of the 5-LO en- 
zyme and/or from increased availability of free arachidonate. 
It must be stressed,  however,  that in PMN  stimulated by 
soluble agonists such as FMLP, C5a, or PAF, the synthesis 
of 5-LO products is primarily dependent on AA availability 
as demonstrated in experiments where the addition of exog- 
enous substrate leads to a dramatic increase in 5-HETE and 
LT synthesis (51, 52, 59-61).  Accordingly, in previous studies 
increases in AA levels  were observed in GM-CSF-primed PMN 
stimulated with PAF (62) and TNF-ot was shown to prime 
PLA2 activation in neutrophils (58).  In the present study, 
measurement of AA by mass  spectrometry demonstrated 
striking differences in free AA levels between LPS-primed 
cells and unprimed cells after FMLP stimulation. Such data 
strongly suggest that enhanced synthesis of 5-LO products 
in LPS-primed PMN may be explained on the basis of in- 
creased substrate availability. Nevertheless,  the possible con- 
tribution of an enhanced ability to transform the free AA 
(i.e., an increased 5-LO activity) cannot be ruled out. Studies 
are now in progress to elucidate the mechanism by which 
LPS prime PMN for enhanced AA availability and to assess 
the possible actions of LPS at the level of the 5-LO enzyme 
and of its activation process. 
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